Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ+ thalassemia with IVS1-5(G→C) mutation

Pediatric Blood and Cancer

Volumn 62, Issue 6, 2015, Pages 1017-1023

  Dehury, Snehadhini ^a   Purohit, Prasanta ^a   Patel, Siris ^a   Meher, Satyabrata ^a   Kullu, Bipin Kishore ^a   Sahoo, Lulup Kumar ^a   Patel, Nayan Kumar ^a   Mohapatra, Alok Kumar ^a   Das, Kishalaya ^a   Patel, Dilip Kumar ^a  

^a VSS Medical College & Hospital   (India)

Author keywords

Fertility; HbF; HbS + thalassemia; Hydroxyurea; Low dose; Vaso occlusive crisis (VOC)

Indexed keywords

BILIRUBIN; HEMOGLOBIN F; HYDROXYUREA; LACTATE DEHYDROGENASE; HEMOGLOBIN S;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; BONE MARROW TOXICITY; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FERTILITY; GENE MUTATION; GONADAL DISEASE; HOSPITALIZATION; HUMAN; LEUKOCYTE; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; NEPHROTOXICITY; NEUTROPHIL COUNT; PREGNANCY OUTCOME; PRIORITY JOURNAL; REPRODUCTION; SICKLE CELL BETA THALASSEMIA; SKIN TOXICITY; SPERM; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ADOLESCENT; BLOOD; GENETICS; MUTATION; PRESCHOOL CHILD; PROSPECTIVE STUDY; THALASSEMIA;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; FERTILITY; HEMOGLOBIN, SICKLE; HUMANS; HYDROXYUREA; MALE; MUTATION; PROSPECTIVE STUDIES; THALASSEMIA;

EID: 84927796730     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25391     Document Type: Article

References (43)

1. Weatherall DJ, Clegg JB, Kwiatkowski D. The role of genomics in studying genetic susceptibility to infectious disease. Genome Res 1997: 7:967-973.
2. rd ed. Oxford: Oxford University Press 2001. pp 456-470.
3. th ed. Oxford: Blackwell Science 2001. pp 393-449.
4. Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S. Candidate sequence variants, fetal hemoglobin in children with sickle cell disease treated with hydroxyurea. PLoS One 2013: 8:e55709.
5. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984: 74:652-656.
6. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program 2009: 2009: 62-69.
7. Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol 2013: 161:852-860.
8. Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LaSHS). Blood 2010: 115:2354-2363.
9. Rigano P, Pecoraro A, Calvaruso G, Steinberg MH, Iannello S, Maggio A. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: A single center prospective survey in adult Italians. Am J Hematol 2013: 88:E261-E264.
10. Purohit P, Mashon RS, Patel S, Dehury S, Pattanayak C, Das K, Nair S, Italia K, Bag S, Colah R, Patel DK. Clinical and molecular characterization of HbHofu in eastern India. Int Jnl Lab Hem 2014: 36:71-76.
11. Meher S, Patel DK, Patel S, Dehury S, Purohit P, Das K. Epidemiology of beta thalassaemia trait in eastern India. Odisha Physician Journals 2012: 9:24-29.
12. Purohit P, Dehury S, Patel S, Patel DK. Prevalence of deletional alpha thalassemia and sickle gene in a tribal dominated malaria endemic area of eastern India. ISRN Hemat 2014: 2014:ID 745245.
13. Patel DK, Mashon RS, Patel S, Das BS, Purohit P, Bishwal SC. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India. Hemoglobin 2012: 36:409-420.
14. Patel S, Purohit P, Mashon RS, Dehury S, Meher S, Sahoo S, Dash SS, Das K, Das P, Patel DK. The effect of hydroxyurea on compound heterozygotes for sickle cell-hemoglobin D-Punjab-A single centre experience in eastern India. Pediatr Blood Cancer 2014: 61:1341-1346.
15. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995: 332:1317-1322.
16. Charache S, Terrin ML, Moore RD, Dover GJ, McMahon RP, Barton FB, Waclawiw M, Eckert SV. Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. Control Clin Trials 1995: 16:432-446.
17. Wu DY, Ugozzoli L, Pal BK, Wallace RB. Allele-specific enzymatic amplification of b-globin genomic DNA for diagnosis of sickle cell anemia. Proc Natl Acad Sci USA 1989: 86:2757-2760.
18. Old JM. Screening and genetic diagnosis of haemoglobin disorders. Blood Rev 2003: 17:43-53.
19. Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, Haugen TB, Kruger T, Wang C, Mbizvo MT, Vogelsong KM. World Health Organization reference values for human semen characteristics. Hum Reprod Update 2010: 16:231-245.
20. Braga LB, Ferriira AC, Guimaraes M. Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia: A Portugese hospital study. Hemoglobin 2005: 29:171-180.
21. +thalassaemia in Orissa State, India. Br J Haematol 1991: 77:215-220.
22. Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R. Hydroxyurea in sickle cell disease-A study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis 2009: 42:25-31.
23. Mabaera R, West RJ, Conine SJ, Macari ER, Boyd CD, Engman CA, Lowrey CH. A cell stress signaling model of fetal hemoglobin induction; what doesn't kill red blood cells makes them stronger. Exp Hematol 2008: 36:1057-1072.
24. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010: 115:5300-5311.
25. Steinberg MH, Lu Z-H, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Blood 1997: 89:1078-1088.
26. Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002: 99:10-14.
27. Adragna NC, Fonseca P, Lauf PK. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood 1994: 83:553-556.
28. Bridges KR, Barabino GD, Brugnara MR, Cho MR, Christoph GW, Dover G, Ewenstein BM, Golan DE, Guttmann CR, Hofrichter J, Mulkern RV, Zhang B, Eaton WA. A multi parameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 1996: 88:4701-4710.
29. Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997: 89:2554-2559.
30. Gurkan E, Tanriverdi K, Baslamisli F. Clinical relevance of vascular endothelial growth factor levels in sickle cell disease. Ann Hematol 2005: 84:71-75.
31. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR. Pain in sickle cell disease. N Engl J Med 1991: 325:11-16.
32. Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: Efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer 2012: 59:365-371.
33. Abbasi AA, Prasad AS, Ortega J, Congco E, Oberleas D. Gonadal function abnormalities in sickle cell anemia. Studies in adult male patients. Ann Intern Med 1976: 85:601-605.
34. Dada OA, Nduka EU. Endocrine function and haemoglobinopathies: Relation between the sickle cell gene and circulating plasma levels of testosterone, luteinising hormone (LH) and follicle stimulating hormone (FSH) in adult males. Clin Chim Acta 1980: 105:269-273.
35. Modebe O, Eze U. Effect of age on testicular function in adult males with sickle cell anemia. Fertil Steril 1995: 63:907-912.
36. Berthaut I, Guignedoux G, Kirsch-Noir F, de Larouziere V, Ravel C, Bachir D, Galactéros F, Ancel PY, Kunstmann JM, Levy L, Jouannet P, Girot R, Mandelbaum J. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008: 93:988-993.
37. Jones KM, Niaz MS, Brooks CM, Roberson SI, Aguinaga MP, Hills ER, Rice VM, Bourne P, Bruce D, Archibong AE. Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints. Int J Environ Res Public Health 2009: 6:1124-1144.
38. Lukusa AK, Vermylen C, Vanabelle B, Curaba M, Brichard B, Chantrain C, Dupont S, Ferrant A, Wyns C. Bone marrow transplantation or hydroxyurea for sickle cell anemia: Long-term effects on semen variables and hormone profiles. Pediatr Hematol Oncol 2009: 26:186-194.
39. Grigg A. Effect of hydroxyurea on sperm count motility morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J 2007: 37:190-192.
40. Charache S, Doverm GJ, Moore RD, Eckert S, Ballas SK, Koshy M, Milner PF, Orringer EP, Phillips G, Jr, Platt OS. Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992: 79:2555-2565.
41. Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Blood 1999: 94:1550-1554.
42. Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004: 103:2039-2045.
43. Mashon RS, Dash PM, Khalko J, Dash L, Mohanty PK, Patel S, Mohanty RC, Das BS, Das UK, Das PK, Patel DK. Higher fetal hemoglobin concentration in patients with sickle cell disease in eastern India reduces frequency of painful crisis. Eur J Haematol 2009: 83:383-384.